New Delhi: Moderna is likely to introduce a single-dose COVID-19 vaccine in India in 2022 while another US giant Pfizer will offer 5 crore jabs in 2021.
At a time when Moderna is discussing with Cipla, among other Indian pharma companies, Pfizer is looking for significant regulatory relaxations including indemnification, according to sources.
However, Moderna has already confirmed to Indian authorities that it lacks surplus vaccines to share this year. Prospects are limited that Johnson & Johnson will export its vaccines from the US to other countries in the near future.
Amid the raging second wave of the COVID-19 pandemic, a couple of rounds of discussions were held last week in meetings chaired by the Cabinet Secretary. The discussions hovered around the availability of vaccines in global as well as domestic markets.
Currently, India is using two jabs — Covishield and Covaxin — to vaccinate the population and has administered 20 crore doses since mid-January.
ALSO READ: Vaccine Update: Panacea Biotec Launches Sputnik V Production In India
